Therachon has welcomed back Inserm Transfert Initiative for its series B round, led by Novo.

Therachon, a Switzerland-based biotechnology developer focused on rare genetic conditions, closed a $60m series B round yesterday that included Inserm Transfert Initiative, the investment arm of research institute Inserm.

Pharmaceutical company Novo Holdings led the round in which Pfizer Ventures, the corporate venturing subsidiary of drug developer Pfizer and French government-owned investment bank Bpifrance also took part.

Additional investors included Cowen Healthcare Investments, Versant Ventures, OrbiMed and funds managed by Tekla Capital Management.

Founded in 2014, Therachon is working on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?